TrialInflammatory bowel diseases2025

Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Bruce E Sands et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.